Industry News

SEATTLE GENETICS (SGEN) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Seattle Genetics, Inc.; Encourages all Investors to Contact the Firm for Information

1h prnewswire
SAN DIEGO, Jan. 21, 2017 /PRNewswire/ -- Johnson & Weaver, LLP announces that a class action complaint was filed on behalf of purchasers of Seattle Genetics, Inc., (NASDAQ: SGEN) securities during the period between October 27, 2016, and December 23, 2016, inclusive (the "Class Period"). Seattle Genetics, a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide.

How Will Pfizer Inc. Fare Under President Trump?

2h fool
President Trump could shake up the pharmaceutical world. If he delivers on his promises, it means that Pfizer (NYSE:PFE), one of the biggest of the big pharma companies, is in for some significant changes. How might Pfizer fare in a Trump Administration?

9 Dividend Stocks Increasing Payouts — O CVS SHLX ED PSXP ZTS VNO CMS EQM

3h investorplace
After a blistering rise immediately following the election in November, the S&P 500 Index has remained range-bound for more than a month. Investors were awaiting President Donald Trump’s inauguration and a slew of earnings reports coming up later in January. Despite the market’s stagnation, a number of companies continued paying higher dividends to shareholders.

Open Square Capital Up 31 Percent In Inaugural Year As Bullish Oil Bets Pay Off

4h seekingalpha
2016...what a year. Just after we sent out our holiday letter, the fund's performance climbed higher in December and we ended on a positive note:

3 Stocks That Tripled

5h fool
The stock market had a good year in 2016, with double-digit percentage returns rewarding investors who stayed invested despite the aging bull market. Yet even though those gains are solid, they pale in comparison to the much larger increases in share prices that some individual stocks saw. In particular, Freeport-McMoRan (NYSE:FCX), SodaStream International (NASDAQ:SODA), and Array BioPharma (NASDAQ:ARRY) have all tripled in value over the past 12 months, and different factors led to their respective success.

Johnson & Johnson Earnings Preview: Don't Expect Big Surprises

7h seekingalpha
Our price estimate of $115 for Johnson & Johnson is roughly in line with the market.

Q4 Earnings Growth the Highest in 8 Quarters

7h zacks
The Q4 earnings season has gotten off to a good start, with earnings and revenue growth tracking above other recent periods and on track to reach the highest level in 8 quarters. Positive surprises, particularly on the earnings front, are a bit on the low side relative to historical periods at this stage. We will see if this trend continues this week as we enter the heart of the earnings season, with more than 300 companies coming out with quarterly results, including 105 S&P 500 members.

Galmed: A Likely 2017 Runner

7h seekingalpha
Data for Phase 2b study of lead drug Aramchol in 240 NASH patients due in second quarter of 2018.

PRO Weekly Digest: Investing In SPACs With Dane Capital Management

8h seekingalpha
How to take advantage of the mispricing in SPACs, the differences in the due diligence process and the importance of having a variant view are topics discussed; Dane Capital shares a long idea on Pace Holdings.

Voyager Therapeutics provides updates on early-stage trial of VY-AADC01 for Advanced Parkinson’s Disease

12h seekingalpha
Voyager Therapeutics (NASDAQ:VYGR) announces updates regarding the Phase 1b study of VY-AADC01 for patients with advanced Parkinson’s disease.

Pluristem increases underwriting deal with Wainwright to $15M; shares down 17% premarket

12h seekingalpha
Pluristem Therapeutics (NASDAQ:PSTI) amends its underwriting agreement with H.C. Wainwright to increase its "bought deal" offering to $15M. Under the bought deal arrangement, Wainwright will purchase the entire offering of 12,244,898 common shares at $1.225. It will also receive warrants to purchase up to 7,346,939 common shares at $1.40. Gross proceeds will be $15M.

Enrollment underway in late-stage study assessing Global Blood's GBT440 in sickle cell disease

12h seekingalpha
The first patient has been enrolled in Global Blood Therapeutics' (NASDAQ:GBT) Phase 3 clinical trial, HOPE, evaluating lead product candidate GBT440 in people with sickle cell disease (SCD) who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year. The primary endpoint is the proportion of participants who achieve more than a 1 g/dL increase in hemoglobin at week 24 compared to baseline.

Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees to pay $625M plus royalties

13h seekingalpha
Bristol-Myers Squibb (NYSE:BMY) and Ono Pharmaceutical Company, Ltd. reach a global patent settlement with Merck (NYSE:MRK) related to cancer med Keytruda (pembrolizumab). BMY and Ono claimed that Keytruda, a PD-1 antibody, infringed on their patents related to the use of PD-1 antibodies [BMY's is Opdivo (nivolumb)] to treat cancer in the U.S., Europe, Australia and Japan.

Infinity Pharma's lead product candidate IPI-549 shows encouraging results in preclinical cancer testing; shares ahead 21%

13h seekingalpha
Infinity Pharmaceuticals (INFI +21.3%) is up on triple normal volume in response to its announcement of positive preclinical data for lead oncology candidate IPI-549. The results were presented at the Keystone Symposia Conference "PI3K Pathways in Immunology, Growth Disorders and Cancer" in Sante Fe, New Mexico.

Johnson & Weaver, LLP Initiates Investigations of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited and Inotek Pharmaceuticals Corp.

14h prnewswire
SAN DIEGO, Jan. 20, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited, and Inotek Pharmaceuticals Corp., as detailed below:

EMA to review Gilead's marketing application for HCV med SOF/VEL/VOX

15h seekingalpha
The European Medicines Agency (EMA) accepts for review Gilead Sciences' (NASDAQ:GILD) Marketing Authorization Application (MAA) seeking approval of its once-daily single-table regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV) infection. The MAA has accelerated review status which shortens the review clock to 150 days from the usual 210 days.

AbbVie hikes Humira price over 8%

15h seekingalpha
In what it says will be the only hike this year, AbbVie (ABBV -0.2%) raises the price of top seller Humira (adalimumab) 8.4%. It usually bumps the price twice annually, most recently by 9.9% and 7.9%. Ten years ago, a Humira pen injector with two syringes sold for $1,258 while today the tab is $4,441, a compounded price gain per year of over 13%.

Diffusion Pharma another bio nano cap on the move; shares up 2.5-fold in two weeks

15h seekingalpha
The remarkable up moves in tiny biotechs this month includes nano cap Diffusion Pharmaceuticals (OTCQX:DFFN +18.2%). Shares almost tripled on January 10 before retracing 73%. With today's move, prices are still ahead 154% since January 9.

Teva Has Got Potential - And The Complexity To Go With It

15h seekingalpha
When Teva Pharmaceutical (NYSE:TEVA) acquired the Actavis generic drug business from Allergan (NYSE:AGN) in August 2016, the Company not only paid a big financial price ($40.5 billion using $33.75 billion cash and $6.75 billion in TEVA's stock), but it also paid a big operational price. The US Federal Trade Commission would only clear the transaction after TEVA agreed to divest one or more strengths of 79 different drugs.

JPMorgan trims views on Teva and Endo; shares steady premarket

16h seekingalpha
JPMorgan downgrades Teva Pharmaceutical Industries (NYSE:TEVA) and Endo International (NASDAQ:ENDP) to Neutral from Overweight citing the need for a "clearer picture of fundamentals." Price targets have been lowered to $40 (20% upside) and $20 (55% upside), respectively.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

16h accesswire
IRVINE, CA / ACCESSWIRE / January 20, 2017 / Khang & Khang LLP (the "Firm") announces that it is filing a class action lawsuit against Agile Therapeutics, Inc. ("Agile" or the "Company") (NASDAQ: AGRX) concerning possible violations of federal securities laws, on behalf of investors who purchased or otherwise acquired Agile shares between March 9, 2016 and January 3, 2017 inclusive (the "Class Period").

SGEN EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm

16h accesswire
LOS ANGELES, CA / ACCESSWIRE / January 20, 2017 / Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.

Amarin announces debt restructuring and private placement of exchangeable senior notes

17h seekingalpha
Amarin (NASDAQ:AMRN) announces that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company, have entered into purchase agreements with certain investors pursuant to which Corsicanto will issue and sell $30M in aggregate principal amount of 3.50% Exchangeable Senior Notes due 2047 guaranteed by Amarin, at par.

Concert Pharma's CTP-656 an Orphan Drug for cystic fibrosis; shares up 8% premarket

17h seekingalpha
Thinly traded micro cap Concert Pharmaceuticals (NASDAQ:CNCE) is up 8% premarket, albeit on only 1,170 shares, in response to its announcement that the FDA has designated Phase 2-stage CTP-656 an Orphan Drug for the treatment of cystic fibrosis. Among the benefits of Orphan Drug status is a seven-year period of market exclusivity in the U.S. for the indication, if approved.

Can Johnson & Johnson Sustain Its Growth in 2017?

17h fool
Johnson & Johnson (NYSE:JNJ) has become a colossus in the healthcare industry with its exposure to the pharmaceutical, medical device, and consumer over-the-counter health-products markets combining to make the company a force to be reckoned with. Yet although the stock performed well in 2016, gaining 15% for the year, J&J shares lost ground in the second half of the year. Now, some investors are worried that harsher drug-pricing regulations could eat into profits in what has been J&J's biggest source of growth recently.